Introduction
Among billions of bone marrow (BM) cells a small fraction of primitive hematopoietic stem cells (HSC) exists that provide self-renewal, differentiation capacity and a constant supply of the whole cell spectrum of all hematopoietic lineages throughout our life. HSC are an ideal target for autologous and allogeneic transplantation, purging strategies, gene transfer and -with recent results on the plasticity of HSC -for organ replacement therapies. The understanding of mechanisms underlying their extensive proliferative capacity, their multilineage differentiation and self-renewal and their further characterization are keenly pursued. Since specific markers of the unique functional properties of HSC have not yet been identified, their detection and enumeration require the use of retrospective assays.
The cell surface sialomucin-like adhesion molecule CD34 has been used as a convenient marker for HSC. [1] [2] [3] The CD34 antigen is expressed on 1-5% of mononuclear BM cells, on a subpopulation of hematopoietic cells, both HSC and early committed progenitors.
3 CD34 + cells have been shown to possess colony-forming potential in short-term assays, 1 maintain long-term colony forming potential in in vitro cultures 4 and allow the differentiation of blood cell lineages in immunocompromised mice. numerous other assays that measure the stem cell activity have been exploited. [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] Clonal analyses using limiting dilution assays in Dexter-like cultures have been used (quality analysis), however, these are time-consuming due to the number of flasks that have to be analyzed. 26, 27 In the past, HSC have been characterized with respect to their ability to form spleen colonies in irradiated mice (CFU-S). Within various CFU-S types, most primitive HSC show marrow repopulating ability (MRA), resistance to 5-FU, low retention of the supravital fluorochrome rhodamine-123 (Rh-123) and are defined as pre-CFU-S. 26, 28 HSC have also been isolated by means of stroma-dependent long-term bone marrow cultures (LTBMC), either by weekly assessment of cobblestone area-forming cells (CAFC) 26, 29, 30 or clonogenic cell output (determined by assessment of 5-8-week-old cultures; LTC-IC). 31 In these frequency analyses, early CAFC were found to be highly sensitive to 5-FU, whereas week 5-8 CAFC were observed in the CD34 + Rh-123 dull HLA-DR low fraction. 26, 29, 30 More recently, in vivo long-term marrow repopulating assays have been exploited in which the capacity of cells to reconstitute the hematopoietic system of host animals are measured. Of these, the sheep in utero transplantation system is used, in which human HSC are transferred into the sheep fetus in utero and are followed for the presence or absence of human blood cells after the sheep is born. 32 Nevertheless, the human sheep xenograft model has limitations: it is not readily accessible, laborious, restricted to few institutions and therefore has not been useful clinically. A popular alternative for investigating the phenotype of human HSC is the nonobese diabetic mice with severe combined immunodeficiency disease (NOD/SCID) assay. 33 This model is more accessible and allows detection of myeloid and lymphoid progeny within 6 weeks and at high efficiency. Limiting dilution analyses in this model have shown that the human cell engraftment is quantitative, independent of exogenous cytokine administration, and attributable almost exclusively to the CD38 − subset of CD34 + cells. 5, 34, 35 Nevertheless, CD34 − human HSC capable of repopulating NOD/SCID mice 34, 36, 37 and fetal sheep 38 have also been detected.
Historical data and results from CD34 positive hematopoietic stem cell research
From early experimental results it became apparent that BM can be used to rescue lethally irradiated mice, and that BMderived HSC form splenic nodules in irradiated recipients and allow hematopoietic reconstitution after radiation-induced hematopoietic failures. 27, 39 HSC were later discovered to represent only a fraction of hematopoietic cells of BM, mobilized peripheral blood (mPB) or umbilical cord blood (CB). Initial characterization of HSC was done on the basis of Rh-123 exclusion 26, 27 or lectin affinity and showed that CFU-S-8, CFU-S-12 and marrow repopul-Leukemia ating cells or pre-CFU-S were physically largely separable. [26] [27] [28] [29] In addition, HSC were characterized using their expression of specific surface markers, such as in the mouse with the complete absence of hematopoietic lineage markers, the expression of the stem cell antigen (Sca-1) and low expression of Thy-1. [6] [7] [8] [9] [10] [11] [12] [13] After the successful hematopoietic reconstitution of baboons with selected CD34 + BM, CD34 + cells became the hallmark of murine and human HSC. 40 Donnelly et al 41 + HSC, the use of CD34 as a marker for HSC and the long-term effects of CD34 + selection in human transplant settings. [49] [50] [51] [52] [53] Recently, selection of cells based on the rapid efflux of the fluorescent DNA-binding dye Hoechst 33342 (HO) has allowed the identification of a distinct cell population with long-term repopulating activity termed side-population (SP). 53, 54 The SP phenotype is due to the selective expression of ABC-G2/BCRP on HSC, which like the MDR/P-glycoprotein is a verapamil-sensitive member of the ABC transporter family. SP cells have long-term repopulating activity in mice, and largely lack CD34 expression. 53, 54 In an attempt to characterize SP cells further, we and others found that human SP cells are mostly CD34
− and CD38 − , as well as negative for CD3, CD14, glycophorin A, AC133 or CD90. In CFU assays, we did not observe highly increased colony-forming potential. 55 In 
CD34
− SP cells are nearly depleted of a CFU potential. 57 It has also been demonstrated that common lymphocyte progenitors are present within the CB SP population. 57 These may dilute the CFC in the human SP population, thereby leading to the low CFU readout. The most likely reason for the low CFU potential, however, is the immature SP phenotype, which does not allow these cells to grow in methylcellulose without prior differentiation in short-term suspension culture. Suspension culture leads to the maturation of less primitive progenitors, 54 and with day 5 and day 7 expanded cells to an increased CFU potential. 36, 55 For LTC-IC, we observed the highest enrichment with apheresis (AP) specimens compared with CB or BM SP cells, 55 in line with the finding that the LTC-IC potential of unsorted AP cells is higher as compared with CB or BM. 58 Storms et al 57 
Lin
− BM cells can reconstitute the lymphohematopoietic system for at least 10 months in 21% of lethally irradiated mice, whereas the majority of CFCs, CFU-S and progenitors, able to provide early but unsustained multilineage engraftment, were recovered among the CD34 + subset. Thus, while CD34 − HSC were unable to provide shortterm engraftment, they sustained long-term multilineage engraftment. To reconcile this observation, Morel et al 61 − HSC and demonstrated that CD34 + TLS are highly enriched for CFC, CFU-S, cobblestone area forming cells (CAFC) and radioprotective cells and contain half of the CRU in TLS marrow. CD34
− TLS -although depleted of progenitor cells -were highly enriched in HSC with competitive longterm repopulating potential. Although mice transplanted with CD34 + TLS recovered hematopoiesis faster compared with CD34 − TLS, both populations were capable of sustaining longterm multilineage hematopoiesis for at least 6 months in primary and 5 months in secondary recipients. 61 The issue supporting the existence of long-term repopulating cells only in the CD34 − cell fraction, as opposed to longterm repopulating cells in both CD34
+ and CD34 − fractions, 12, 14, 41, 61 has become even more complex with initial reports on murine CD34
− HSC that could be induced to express CD34 and increase their engraftment capacities following exposure to 5-FU or cytokines. 62 , 63 Sato et al 62 
found that long-term engraftment cells reside in the CD34
− population. He hypothesized that murine CD34 − HSC exist in an extremely quiescent state, and that activation is required to cause an induction of cells, thereby making the latter more readily able to engraft in mice (Table 1) In contrast to primitive human BM HSC which are predominantly CD38 −/low , long-term reconstituting murine stem cells express high levels of CD38, which suggests differences of human and murine cells in the expression of cell surface markers. Also, the coexpression of subpopulation with other markers, such as Sca-1 and c-kit, [61] [62] [63] [64] as compared with Lin − CD34 + /CD34 − cells does not seem to identify the same long-term repopulating capability cell population. 13, 41, 48, 64, 65 Early discrepancies with respect to results on CD34
+ and CD34
− cells may also be due to the low but detectable levels of CD34 which can cause overlap in purified subsets. 12, 14, 41, [60] [61] [62] [63] [64] [65] [66] [67] [68] Differences in the sensitivity of the in vivo engraftment assays may also be related to the lack of administration of accessory cells, administration of cytokines to the transplanted mice, experimental manipulation of the HSC cell preparation and/or myeloablative treatment of mice. 36, [38] [39] [40] [41] [60] [61] [62] [63] In addition, differences in the long-term repopulation ability of CD34
+ and CD34 − cells may result from antibody staining irregularities so that clear guidelines for analyzing CD34
− vs CD34 + cells seem appropriate. 36, [38] [39] [40] [41] [60] [61] [62] [63] Moreover, if Lin − CD34 − cells are not isolated with utmost care and contain one single or very few CD34
+ cells, the latter may account for the HSC activity within the CD34 − population. These variations underscore the necessity that further work is needed to characterize murine and human HSC, and to most ideally find a marker for positive selection of CD34 − HSC.
Discussion and conclusions

Although evidence that CD34
− cells represent HSC still appears immature, xenogenic human sheep in utero transplantation, 38 murine studies by Osawa et al, 60 demonstration of CD34
− HSC in NOD/SCID 36,61,62 and development of CD34 + cells with culture of initially CD34 − HSC, [62] [63] [64] 66 suggest that HSC activity exists within the murine and human Lin − CD34 − population. This redirects us to consider which cell population to select. If HSC exist within the CD34 − population, the enrichment of CD34 + cells -current practice in stem cell transplantation and to date one of the most efficient and effective cell separation methods -may be of concern, since this may result in a loss of at least a portion of HSC. On the other hand, thousands of successful autologous and allogeneic transplantations with use of CD34 + selected cells makes the use of CD34 + HSC still valid. One reason among others of the apparent CD34
+ vs CD34
− controversies -at least in the murine system -seems related to their activation and/or cycling state. [65] [66] [67] [68] [69] [70] [71] Accepting recent work that indicates that CD34
− HSC indeed exist, 62 and if this applies to human HSC also, the CD34 + selection may be appropriate to distinguish potent HSC from quiescent stem cells or mesenchymal precursors. Thus, if the human CD34 expression pattern mirrors that in the murine system, quiescent CD34 − HSC should be found in the BM which will, as their CD34 + counterpart, be activated with regard to proliferation and differentiation. Recent results on G 0 and G 1 CB CD34
+ cells have revealed a more than 1000-fold difference in GM-CFC, 250-fold higher number of BFU-E and 600-fold higher expansion potential of G 0 compared to G 1 cells. This suggests that HSC reside preferentially in the G 0 phase of the cell cycle. 68 This has also been convincingly shown by Glimm et al, 69 who demonstrated that human CB cells transiting the S/G 2 /M phases of the cell cycle after growth factor stimulation -due to a reversible silencing of the engraftment potential of HSC present in these populations -do not reenter G 0 and do not repopulate the BM of irradiated NOD/SCID mice.
Finally, results demonstrating a variation in the engraftment potential of CD34 + and Lin − CD34 − cells in fetal sheep recipients with respect to the source of progenitors are of interest: when serial transplants are performed in sheep fetus, the engraftment occurs earlier with mPB CD34
+ than BM and is lower with PB CD34 + and Lin − CD34 − than BM cells. 70 Whereas comparable CFC, LTC-IC or cobblestone area forming cells per CD34 + cells are similar in mPB and BM, generation of secondary CFC from an individual LTC-IC in mPB is significantly lower than that of BM. Previous studies have distinguished distinct classes of HSC with different engraftment properties: of these, long-term repopulating cells (LTRC) have a lifelong ability to produce all blood cells and generate progeny that display similar potentialities upon transfer to secondary and tertiary recipients. Other cells with similar differentiation potentialities may reconstitute both myeloid and lymphoid compartments, but typically for less than 4 months. Additional types of short-term repopulating cells (STRC), that are either myeloid or lymphoid restricted have also been identified. 34, [71] [72] [73] [74] [75] In order to distinguish these distinct HSC classes, transplants in NOD/SCID-␤2 microglobulin-null (NOD/SCID-␤2m −/− ) mice showed that repopulation of three distinct HSC takes place: one of myeloid restriction (STRC-M) and one with dual myeloid and lymphoid-repopulating ability (STRC-ML), neither of which efficiently engrafted NOD/SCID mice. 34 In addition, NOD/SCID-␤2m −/− were engrafted after 6-8 weeks by more primitive LTRC-ML that engraft NOD/SCID mice equally efficiently. Of interest was that in mPB both STRC-M and STRC-ML activities were markedly elevated as compared with BM or CB. This relatively elevated STRC content of mPB seems to explain the apparently faster rates of hematopoietic recovery. 34 Although the frequency of HSC with primary long-term repopulation may thus be lower in mPB than BM, supported by serial transplantation experiments which have exhausted the repopulating ability of Lin −
CD34
+ cells from PB faster than from BM, 70 in the clinical setting, where large doses of PB MNC or CD34 + cells are given, these have been shown to contain sufficient cells with long-term engraftment potential.
Perspective
Transplants of hematopoietic cells have assumed an important role in the treatment of many malignancies. They hold much promise for the clinical application involving gene therapy, tolerance induction to facilitate allogeneic or xenogenic organ transplants and other modalities, where HSC purification and/or expansion before transplantation is desirable. Recently, exciting data have demonstrated that the potential of HSC is almost unlimited to generate whole organ systems. [76] [77] [78] [79] Therefore, the potential of CD34 − and CD34 + HSC also lies within their apparent capacity of transdifferentiation to cells of widely diverse tissues, such as BM-derived mesenchymal cells, already used to treat osteogenesis imperfecta in children, 79 as a source of hepatic oval cells, 80 for cardiocytes, 81 neural cells 82, 83 and vice versa. 84 Although the frequency of HSC, with respect to SP, Lin Deciding which BM, PB or CB population to select is an important (pre)clinical issue. Current results to date, as summarized in this paper, suggest only performing CD34 selections for transplant purposes when alternative methods are not available.
Much energy still needs to be placed in the CD34 − isolation to best ensure that the latter is as pure as possible. This and the characterization of HSC will need further extensive investigation to finally clarify the value of CD34 − cells.
